Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #72 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Hikal Limited (this stock) | 2,644 | — | -4.1% | -15.3% | — | 38 | 75 | 33 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 403 | -10 | -7 | ₹ |
| March 31, 2026 | 519 | 8 | 14 | ₹ |
| Dec. 31, 2025 | 494 | -9 | -6 | ₹ |
| Sept. 30, 2025 | 318 | -47 | -35 | ₹ |
| June 30, 2025 | 380 | -30 | -22 | ₹ |
| March 31, 2025 | 552 | 68 | 50 | ₹ |
| Dec. 31, 2024 | 448 | 24 | 17 | ₹ |
| Sept. 30, 2024 | 453 | 25 | 18 | ₹ |
| June 30, 2024 | 407 | 7 | 5 | ₹ |
| March 31, 2024 | 514 | 47 | 34 | ₹ |
| Dec. 31, 2023 | 448 | 22 | 16 | ₹ |
| Sept. 30, 2023 | 435 | 17 | 13 | ₹ |
| June 30, 2023 | 388 | 10 | 7 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 1,713 | -78 | -49 |
| March 31, 2025 | 1,860 | 124 | 91 |
| March 31, 2024 | 1,785 | 96 | 70 |
| March 31, 2023 | 2,023 | 105 | 78 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 302 | -145 | -160 | 148 | 154 |
| March 31, 2025 | 280 | -136 | -144 | 137 | 143 |
| March 31, 2024 | 187 | -174 | -27 | 204 | -17 |
| March 31, 2023 | 315 | -292 | -8 | 303 | 13 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 2,365 | 1,199 | 1,174 | 308 | 373 | 884 | 679 | 10 | 1,327 | 358 |
| March 31, 2025 | 2,529 | 1,262 | 1,238 | 395 | 367 | 995 | 790 | 13 | 1,357 | 334 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
